Market capitalization | $1.12b |
P/B ratio (TTM) P/B ratio | negative |
Cash position | $130.53m |
P/E forward | negative |
P/S forward | 1,571.39 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Septerna forecast:
4 Analysts have issued a Septerna forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.18 0.18 |
500%
500%
|
|
Gross Profit | -0.19 -0.19 |
5%
5%
|
|
EBITDA | -22 -22 |
88%
88%
|
EBIT (Operating Income) EBIT | -23 -23 |
87%
87%
|
Net Profit | -21 -21 |
87%
87%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Jeffrey Finer |
Website | www.septerna.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.